Caficrestat is under clinical development by Applied Therapeutics and currently in Phase III for Diabetic Peripheral Neuropathy. According to GlobalData, Phase III drugs for Diabetic Peripheral Neuropathy have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Caficrestat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Caficrestat overview
Caficrestat (AT-001) is under development for the treatment of diabetic complications including type 2 diabetes, diabetic cardiomyopathy, diabetic peripheral neuropathy, acute myocardial infarction (liquid formulation), acute lung inflammation and cardiomyopathy in critical COVID-19 infections. The drug candidate acts by targeting aldose reductase. It is administered through an oral and subcutaneous route. It was under development for congestive heart failure in adults.
Applied Therapeutics overview
Applied Therapeutics is a clinical-stage biopharmaceutical company that develops novel drug candidates against validated molecular targets. The company’s pipeline products include govorestat (AT-001), an investigational novel aldose reductase inhibitor that targets diabetic peripheral neuropathy and diabetic cardiomyopathy (DbCM); govorestat for sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 deficiency (PMM2-CDG); and AT-003 aldose reductase inhibitor (ARI) treats diabetic retinopathy. Applied Therapeutics is headquartered in New York, the US.
For a complete picture of Caficrestat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
